- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07924189
Association of Psychological Distress With Clinical Outcomes in Patients With Digestive System Cancers
Association of Psychological Distress With Clinical Outcomes in Patients With Digestive System Cancers: A Prospective Cohort Study
This prospective observational cohort study aims to investigate the association between psychological distress and clinical outcomes in patients with digestive system cancers, including pancreatic, gastric, and colorectal cancers.
Approximately 100 adult patients who are scheduled to receive first-line systemic anticancer therapy will be enrolled at Xuanwu Hospital, Capital Medical University. Psychological distress will be assessed using the Distress Thermometer (DT), Hospital Anxiety and Depression Scale (HADS), and 12-item General Health Questionnaire (GHQ-12).
Participants will undergo baseline assessments and follow-up evaluations every three months for up to three years. Clinical information, psychological distress scores, laboratory findings, imaging results, and quality-of-life data will be collected.
The primary outcome is progression-free survival (PFS). Secondary outcomes include overall survival (OS), objective response rate (ORR), and quality of life. The study will evaluate whether psychological distress is associated with cancer prognosis after adjusting for potential confounding factors, including cancer stage, treatment regimen, and nutritional status.
As an observational study, no experimental treatment will be assigned, and all participants will receive standard anticancer treatment according to routine clinical practice.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 24266
- Xuanwu Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The study population will consist of approximately 100 adult patients with pathologically confirmed pancreatic, gastric, or colorectal cancer who are scheduled to receive first-line systemic anticancer therapy at the Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Eligible patients will be consecutively enrolled according to the predefined inclusion and exclusion criteria. Psychological distress will be assessed at baseline and during follow-up to investigate its association with clinical outcomes, including progression-free survival and overall survival.
Beskrivelse
Inclusion Criteria:
- Patients with pathologically confirmed digestive system cancers, including pancreatic cancer, gastric cancer, or colorectal cancer.
- Male or female patients aged 18 years or older.
- Patients scheduled to receive first-line systemic anticancer therapy, including chemotherapy, targeted therapy, immunotherapy, or combination therapy, with no systemic treatment for the current cancer lesions within 3 months prior to enrollment.
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Life expectancy of at least 12 weeks, as assessed by the investigator.
- Willing and able to provide written informed consent to participate in the study.
Exclusion Criteria:
- History of another malignancy within the past 3 years or concurrent malignancy.
- Presence of acute or chronic psychiatric disorders, or current treatment with antidepressant or anxiolytic medications.
- Previous treatment in another investigational drug trial.
- Inability to complete psychological assessment questionnaires due to cognitive impairment, language barriers, or other conditions that interfere with questionnaire completion.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsramme: From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed up to 3 years.
|
Progression-free survival (PFS) is defined as the time from study enrollment to the first radiologically confirmed disease progression, as assessed by the investigator according to RECIST version 1.1, or death from any cause, whichever occurs first. PFS will be compared between patients with high and low levels of psychological distress. |
From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed up to 3 years.
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Neoplasmer etter nettsted
- Neoplasmer
- Tarmsykdommer
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Magesykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Kolonsykdommer
- Neoplasmer i magen
- Kolorektale neoplasmer
- Neoplasmer i bukspyttkjertelen
Andre studie-ID-numre
- hongyanli3
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .